New contrast agent could mean lower doses for heart MRI
NCT ID NCT05954559
First seen Apr 23, 2026
Summary
This study tests whether a new MRI contrast agent called Elucirem can detect heart scarring as effectively as the standard agent, but at a much lower dose. Researchers will compare images from 25 adults who previously had a heart MRI with the standard agent. If Elucirem works well at half the usual dose, it could mean less contrast agent exposure for patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOCARDIAL FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins Center for Advanced Imaging and Research Science, located in the Science + Technology Park at 1812 Ashland Avenue, Baltimore, MD.
RECRUITINGBaltimore, Maryland, 21202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Johns Hopkins School of Medicine
NOT_YET_RECRUITINGBaltimore, Maryland, 21205, United States
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Elucirem (Gadopiclenol)
What this could lead to
If successful, this could allow doctors to use a lower dose of contrast agent for heart MRI, potentially reducing risks while still accurately detecting heart scarring.
What could go wrong
This is a very small, early-phase study with only 25 participants. The new agent may not perform as well as the standard one at lower doses, and results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.